Abstract:Hepatocellular carcinoma (HCC) is regarded as one of the universal cancers in the world. Therefore, our study is based on clinical, molecular mechanism and immunological perspectives to analyze how NAP1L1 affects the progression of HCC. To begin with, the gene expression datasets and clinical data of GSE14520, GSE76427, ICGC, and TCGA are originated from GEO, ICGC, and TCGA databases. Subsequently, DEG screening was performed on data using R studio, and we finally found that 2,145 overlapping DEGs were screened from four datasets at the end. Then, we used R studio to filter the survival-related genes of the GSE76427 and ICGC datasets, and we screened out 101 survival-related genes. Finally, 33 common genes were screened out from 2,145 overlapping DEGs and 101 survival-related genes. Then, NAP1L1 was screened from 33 common genes using the CytoHubba plug-in in Cytoscape software. Furthermore, ground on GEO, ICGC, and TCGA databases, the survival analysis, clinical feature analysis, univariate/multivariate regression analysis, and multiple GSEA were used to study NAP1L1. The Conclusion claimed that HCC patients with higher expression levels of NAP1L1 had a poorer prognosis than those with lower expression levels. Thus, we believe that NAP1L1 is an independent prognostic factor for HCC. In order to shed light on NAP1L1's molecular mechanism promoting the progression of HCC closely, the GSEA tool was applied to complete the GSEA of the four datasets. Furthermore, the results confirmed that NAP1L1 could promote HCC progression by regulating the G2/M transition of the cell cycle and Wnt signaling pathway. Western blot and flow cytometry were also performed to understand those mechanisms in this study. The result of Western blot showed that NAP1L1 silencing led to downregulation of CDK1 and β-catenin proteins; the result of flow cytometry showed that cell numbers in the G2 phase were significantly increased when NAP1L1 was silenced. Thus, we claimed that NAP1L1 might promote HCC progression by activating the Wnt signaling pathway and promoting cell cycle G2/M transition. In addition, ground on GSE14520 and GSE76427 datasets, and ICGC and TCGA databases, the correlation between NAP1L1 and immune cells was analyzed in HCC patients. At the same time, the TISIDB online database and the TIMER online database were testified to the association between NAP1L1 and immune cells. Hence, the summary shows that NAP1L1 was connected with a certain amount of immune cells. We can speculate that NAP1L1 may influence macrophages to promote HCC progression through some potential mechanisms.

NUP155 and NDC1 interaction in NSCLC: a promising target for tumor progression

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

NUF2 Drives Cholangiocarcinoma Progression and Migration Via Inhibiting Autophagic Degradation of TFR1

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

NPM3 As a Novel Oncogenic Factor and Poor Prognostic Marker Contributes to Cell Proliferation and Migration in Lung Adenocarcinoma

An integrated bioinformatics approach to early diagnosis, prognosis and therapeutics of non-small-cell lung cancer

NUF2 Is a Potential Immunological and Prognostic Marker for Non-Small-Cell Lung Cancer

Evaluation of the roles and regulatory mechanisms of PD-1 target molecules in NSCLC progression

The Role of CEP55 Expression in Tumor Immune Response and Prognosis of Patients with Non-small Cell Lung Cancer.

Nucleoporin 107 Promotes the Survival of Tumor Cells in Cervical Cancers

Analyzing Roles of NUSAP1 from Clinical, Molecular Mechanism and Immune Perspectives in Hepatocellular Carcinoma

NAP1L1 Functions As a Novel Prognostic Biomarker Associated with Macrophages and Promotes Tumor Progression by Influencing the Wnt/β-Catenin Pathway in Hepatocellular Carcinoma.

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis

Analysis of Gene Expression Profiles of Non-Small Cell Lung Cancer at Different Stages Reveals Significantly Altered Biological Functions and Candidate Genes

Nucleoporin 93 Mediates Β-Catenin Nuclear Import to Promote Hepatocellular Carcinoma Progression and Metastasis.

Mechanistic study of NUPR1 in bladder cancer development through transcriptional regulation of CCR2

Survival-based Bioinformatics Analysis to Identify Hub Genes and Key Pathways in Non-Small Cell Lung Cancer

NudCD1 Promotes the Proliferation and Metastasis of Non-Small Cell Lung Cancer Cells through the Activation of IGF1R-ERK1/2

Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis.

NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling